Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder - News Summed Up

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder


ABOUT ERZOFRI®What is ERZOFRI (paliperidone palmitate) extended-release injectable suspension? Whether antipsychotic drug products differ in their potential to cause TD is unknown. Falls : Somnolence, postural hypotension, motor and sensory instability have been reported with the use of antipsychotics, including paliperidone palmitate, which may lead to falls and, consequently, fractures or other fall-related injuries. Potential for Cognitive and Motor Impairment : Antipsychotics, including ERZOFRI, have the potential to impair judgement, thinking, and motor skills. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including ERZOFRI, during pregnancy.


Source: The Bubble July 28, 2024 15:12 UTC



Loading...
Loading...
  

Loading...